These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 34681838)

  • 1. Platelet-Derived PCSK9 Is Associated with LDL Metabolism and Modulates Atherothrombotic Mechanisms in Coronary Artery Disease.
    Petersen-Uribe Á; Kremser M; Rohlfing AK; Castor T; Kolb K; Dicenta V; Emschermann F; Li B; Borst O; Rath D; Müller KAL; Gawaz MP
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PCSK9 Biology and Its Role in Atherothrombosis.
    Barale C; Melchionda E; Morotti A; Russo I
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PCSK9 (Proprotein Convertase Subtilisin/Kexin 9) Enhances Platelet Activation, Thrombosis, and Myocardial Infarct Expansion by Binding to Platelet CD36.
    Qi Z; Hu L; Zhang J; Yang W; Liu X; Jia D; Yao Z; Chang L; Pan G; Zhong H; Luo X; Yao K; Sun A; Qian J; Ding Z; Ge J
    Circulation; 2021 Jan; 143(1):45-61. PubMed ID: 32988222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PCSK9 and atherosclerosis: Looking beyond LDL regulation.
    Ragusa R; Basta G; Neglia D; De Caterina R; Del Turco S; Caselli C
    Eur J Clin Invest; 2021 Apr; 51(4):e13459. PubMed ID: 33236356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors Reduce Platelet Activation Modulating ox-LDL Pathways.
    Cammisotto V; Baratta F; Castellani V; Bartimoccia S; Nocella C; D'Erasmo L; Cocomello N; Barale C; Scicali R; Di Pino A; Piro S; Del Ben M; Arca M; Russo I; Purrello F; Carnevale R; Violi F; Pastori D; Pignatelli P
    Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281247
    [No Abstract]   [Full Text] [Related]  

  • 6. The relationship between the plasma PCSK9 levels and platelet indices in patients with stable coronary artery disease.
    Li S; Zhu CG; Guo YL; Xu RX; Zhang Y; Sun J; Li JJ
    J Atheroscler Thromb; 2015; 22(1):76-84. PubMed ID: 25185779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure and Function of Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) in Hyperlipidemia and Atherosclerosis.
    Lu X
    Curr Drug Targets; 2019; 20(10):1029-1040. PubMed ID: 30767742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platelet function and activation markers in primary hypercholesterolemia treated with anti-PCSK9 monoclonal antibody: A 12-month follow-up.
    Barale C; Bonomo K; Frascaroli C; Morotti A; Guerrasio A; Cavalot F; Russo I
    Nutr Metab Cardiovasc Dis; 2020 Feb; 30(2):282-291. PubMed ID: 31653513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rosuvastatin Reduces Aortic Sinus and Coronary Artery Atherosclerosis in SR-B1 (Scavenger Receptor Class B Type 1)/ApoE (Apolipoprotein E) Double Knockout Mice Independently of Plasma Cholesterol Lowering.
    Yu P; Xiong T; Tenedero CB; Lebeau P; Ni R; MacDonald ME; Gross PL; Austin RC; Trigatti BL
    Arterioscler Thromb Vasc Biol; 2018 Jan; 38(1):26-39. PubMed ID: 29162602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PCSK9 in relation to coronary plaque inflammation: Results of the ATHEROREMO-IVUS study.
    Cheng JM; Oemrawsingh RM; Garcia-Garcia HM; Boersma E; van Geuns RJ; Serruys PW; Kardys I; Akkerhuis KM
    Atherosclerosis; 2016 May; 248():117-22. PubMed ID: 27015246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PCSK9 as an Atherothrombotic Risk Factor.
    Sotler T; Šebeštjen M
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of plasma small dense LDL cholesterol with PCSK9 levels in patients with angiographically proven coronary artery disease.
    Zhang Y; Xu RX; Li S; Zhu CG; Guo YL; Sun J; Li JJ
    Nutr Metab Cardiovasc Dis; 2015 Apr; 25(4):426-33. PubMed ID: 25770756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proprotein convertase subtilisin/kexin type 9 (PCSK9) in lipid metabolism, atherosclerosis and ischemic stroke.
    Zhang L; Song K; Zhu M; Shi J; Zhang H; Xu L; Chen Y
    Int J Neurosci; 2016 Aug; 126(8):675-80. PubMed ID: 26040332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Beyond Lipids: The Role in Oxidative Stress and Thrombosis.
    Cammisotto V; Baratta F; Simeone PG; Barale C; Lupia E; Galardo G; Santilli F; Russo I; Pignatelli P
    Antioxidants (Basel); 2022 Mar; 11(3):. PubMed ID: 35326219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PCSK9 in Haemostasis and Thrombosis: Possible Pleiotropic Effects of PCSK9 Inhibitors in Cardiovascular Prevention.
    Paciullo F; Momi S; Gresele P
    Thromb Haemost; 2019 Mar; 119(3):359-367. PubMed ID: 30605918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased sortilin and its independent effect on circulating proprotein convertase subtilisin/kexin type 9 (PCSK9) in statin-naive patients with coronary artery disease.
    Hu D; Yang Y; Peng DQ
    Int J Cardiol; 2017 Jan; 227():61-65. PubMed ID: 27846466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A transient amphipathic helix in the prodomain of PCSK9 facilitates binding to low-density lipoprotein particles.
    Sarkar SK; Foo ACY; Matyas A; Asikhia I; Kosenko T; Goto NK; Vergara-Jaque A; Lagace TA
    J Biol Chem; 2020 Feb; 295(8):2285-2298. PubMed ID: 31949048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet activation and endothelial dysfunction biomarkers in acute coronary syndrome: the impact of PCSK9 inhibition.
    Ziogos E; Chelko SP; Harb T; Engel M; Vavuranakis MA; Landim-Vieira M; Walsh EM; Williams MS; Lai S; Halushka MK; Gerstenblith G; Leucker TM
    Eur Heart J Cardiovasc Pharmacother; 2023 Nov; 9(7):636-646. PubMed ID: 37468450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of PCSK9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: The PCSK9-REACT study.
    Navarese EP; Kolodziejczak M; Winter MP; Alimohammadi A; Lang IM; Buffon A; Lip GY; Siller-Matula JM
    Int J Cardiol; 2017 Jan; 227():644-649. PubMed ID: 27810295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.